Blocking Fructose Metabolism Shows Promise in Treating Pediatric Brain Cancer

Researchers at Johns Hopkins Medicine have identified a potential new strategy for treating group 3 medulloblastoma, a particularly aggressive and hard-to-treat pediatric brain cancer. In a study published in Acta Neuropathologica Communications, scientists at the Kimmel Cancer Center demonstrated that blocking the ability of tumor cells to metabolize fructose can slow the progression of the disease in mouse models.

Medulloblastoma is the most common malignant brain tumor in children, and group 3 has the worst prognosis among its subtypes. Current treatments, including surgery, radiation, and chemotherapy, often fail to prevent recurrence and can cause long-term side effects in young patients. The new research suggests that targeting the metabolic pathways that fuel tumor growth could offer a more effective and less toxic alternative.

The study focused on how group 3 medulloblastoma cells generate energy. Unlike normal cells, which typically rely on glucose, these cancer cells show a heightened dependence on fructose metabolism. By inhibiting the enzymes involved in fructose breakdown, the researchers were able to significantly reduce tumor growth and improve survival rates in mice.

“Our findings open the door to developing drugs that specifically block fructose utilization in these cancer cells, potentially sparing healthy cells and reducing side effects,” said the lead author of the study in a press release. The team is now working to identify compounds that can safely achieve this in humans.

The announcement has implications for the broader field of oncology, as fructose metabolism is also implicated in other cancers, including glioblastoma. Companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are already exploring similar approaches for brain tumors. CNS Pharmaceuticals is developing next-generation treatments for glioblastoma, the most aggressive form of brain cancer in adults.

The Johns Hopkins study adds to a growing body of evidence that metabolic interventions could complement existing therapies for hard-to-treat cancers. However, the researchers caution that the findings are still preclinical, and human trials will be necessary to confirm the approach’s safety and efficacy.

“This is a promising step, but we have a long way to go before it benefits patients,” the authors noted. The research was supported by grants from the National Institutes of Health and other funding agencies.

For families affected by pediatric brain cancer, the news offers a glimmer of hope. Medulloblastoma accounts for about 20% of all childhood brain tumors, and group 3 remains one of the most challenging to treat. If further studies validate these results, blocking fructose metabolism could become a key component of future treatment regimens.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Blocking Fructose Metabolism Shows Promise in Treating Pediatric Brain Cancer.

The post Blocking Fructose Metabolism Shows Promise in Treating Pediatric Brain Cancer appeared first on citybuzz.